CTIC: Summary for Cell Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 3:37am EST - Canadian Markets open in 5 hours and 53 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Cell Therapeutics Inc. (CTIC)

On Nov 23: 1.12 USD 0.00 (0.00%)

MORE ON CTIC

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cell Therapeutics, Inc. (NCM:CTIC) Delayed quote data

Last Trade:	1.12 USD
Trade Time:	Nov 23
Change:	0.00 (0.00%)
Prev Close:	1.12
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	11.50

Day's Range:	N/A - N/A
52wk Range:	0.05 - 2.23
Volume:	0
Avg Vol (3m):	19,228,600
Market Cap:	643.36M
P/E (ttm):	N/A
EPS (ttm):	-3.53
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add CTIC to Portfolio

Download Data

HEADLINES

•	Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
	PRNewswire (Tue 1:30am)

•	A Big Upgrade for Allos Therapeutics
	at Motley Fool (Mon 9:16am)

•	Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
	Wall Street Transcript (Fri, Nov 20)

•	Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
	PRNewswire (Fri, Nov 20)

•	Judges: Seattle biotech can pursue $23M claim
	AP (Wed, Nov 18)

•	CELL THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Mon, Nov 16)

•	Poniard's CEO Pulls a Belichik: BioBuzz
	at TheStreet.com (Mon, Nov 16)

•	Poniard's CEO Pulls a Belichick: BioBuzz
	at TheStreet.com (Mon, Nov 16)

•	A Closer Look at Cardium's Wound-Healing Drug: BioBuzz
	at TheStreet.com (Mon, Nov 16)

•	Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz
	at TheStreet.com (Mon, Nov 16)

More Headlines for CTIC...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of treatments for cancer. The company offers XYOTAX, a Phase III clinical trial chemotherapeutic agent, which links anti cancer agent called paclitaxel to a pol...

Full Company Profile

Add to Portfolio

Email to a Friend

•